Vericel to Host Fourth-Quarter 2015 Earnings Webcast and Conference Call on March 14, 2016
March 09 2016 - 6:46PM
Vericel Corporation (NASDAQ:VCEL), a leading developer of
patient-specific expanded cellular therapies for the treatment of
severe diseases and conditions, today announced the following
webcast and conference call:
What: |
Vericel Corporation Fourth-Quarter
2015 Earnings Call |
When: |
Monday, March 14, 2016 at 8:00am
(EDT) |
Where: |
http://investors.vcel.com/events.cfm |
How: |
The conference call will be available
live in the Investors section of the Vericel website at
http://investors.vcel.com/events.cfm. Please access the site
at least 15 minutes prior to the scheduled start time in order to
download the required audio software if necessary. |
|
|
|
|
To participate in the live call by
telephone, please call (877) 312-5881 and reference Vericel
Corporation fourth-quarter 2015 investor conference call. If
calling from outside the U.S., please use the international phone
number (253) 237- 1173. |
If you are unable to participate in the live call, the webcast
will be available at http://investors.vcel.com/events.cfm until
March 14, 2017. A replay of the call will also be available
until 11:59 pm (EDT) on March 18, 2016 by calling (855) 859-2056,
or from outside the U.S. (404) 537-3406. The conference ID is
55599059.
About Vericel CorporationVericel Corporation is
a leader in developing patient-specific expanded cellular therapies
for use in the treatment of patients with severe diseases and
conditions. The company markets two autologous cell therapy
products in the U.S.: Carticel® (autologous cultured chondrocytes),
an autologous chondrocyte implant for the treatment of cartilage
defects in the knee, and Epicel® (cultured epidermal autografts), a
permanent skin replacement for the treatment of patients with
deep-dermal or full-thickness burns comprising greater than or
equal to 30% of total body surface area. Vericel is also
developing MACI™, a third-generation autologous chondrocyte implant
for the treatment of cartilage defects in the knee, and
ixmyelocel-T, a patient-specific multicellular therapy for the
treatment of advanced heart failure due to ischemic dilated
cardiomyopathy. For more information, please visit the
company’s website at www.vcel.com.
Epicel® and Carticel® are registered trademarks and MACI™ is a
trademark of Vericel Corporation. © 2016 Vericel
Corporation. All rights reserved.
CONTACT:
Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
or
Lee Stern
The Trout Group
lstern@troutgroup.com
(646) 378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024